Dawn of a New Era for Kinase Drug Discovery: Kinome Wide Profiling and Screening Solutions Coupled to Functional Cell-based Assays Enable Launch of Selective and Functional Kinase Inhibitors
White Paper May 09, 2011
It is no mystery that the global drug discovery market is continuously under pressure to perform against rapidly shifting regulations, timelines and performance data while balancing meaningful innovation and profitability. The industry is rising to the challenge as innovative new drug discovery technologies are fueling continuous improvements across the effectiveness of marketed drugs while minimizing potential adverse side effects. This is where novel product and service portfolios from companies like DiscoveRx® play a pivotal role in offering a range of GPCR and Kinase based tools that give their customers the power to discover new drugs.
Related White Papers
One of the common molecular analyses is the determination of a lead molecule’s binding kinetics and affinity to the target. This warrants the need for analytical instruments capable of characterizing such molecules. Download this whitepaper to discover an approach that accurately measures multiple high-affinity interactions over long run times.READ MORE
Data accessibility has been a challenge because the lab operator’s relationship to data is usually prescribed by preset LIMS features. Using data science algorithms, it is now possible to process and integrate all LIMS and enterprise data to provide valuable insights and timely, meaningful recommendations. Access this whitepaper to discover a technology that provides a holistic view of your data, delivers statistical and business analysis and increases productivity.
Life science R&D is developing incredible solutions to global problems. But this ground breaking work is often being done with outdated tools that weren't designed with the complexity of life science in mind. Let's explore the core questions that R&D organizations are struggling to answer.READ MORE